These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 23905231)

  • 21. Two UK Government proposals bearing on drug safety.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1997 Mar; 16(1):1-7. PubMed ID: 9192053
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of online reporting systems and their compatibility check with respective adverse drug reaction reporting forms.
    Maharshi V; Nagar P
    Indian J Pharmacol; 2017; 49(5):374-382. PubMed ID: 29515278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse reactions: know the risks.
    Shepherd M
    Nurs Times; 2011 Apr 5-11; 107(13):20. PubMed ID: 21678719
    [No Abstract]   [Full Text] [Related]  

  • 24. The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions.
    Candore G; Monzon S; Slattery J; Piccolo L; Postigo R; Xurz X; Strauss S; Arlett P
    Drug Saf; 2022 Jan; 45(1):83-95. PubMed ID: 34881404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Understanding and reducing the risk of adverse drug reactions in pediatric patients].
    Gotta V; van den Anker J; Pfister M
    Ther Umsch; 2015 Dec; 72(11-12):679-86. PubMed ID: 26654811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obstacles to transparency over pharmacovigilance data within the EMA.
    Prescrire Int; 2015 Nov; 24(165):278-9. PubMed ID: 26688911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005].
    Weisser K; Meyer C; Petzold D; Mentzer D; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Nov; 50(11):1404-17. PubMed ID: 17999134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Making medicines safer: analysis of patient reports to the UK's Yellow Card Scheme.
    O' Donovan B; Rodgers RM; Cox AR; Krska J
    Expert Opin Drug Saf; 2019 Dec; 18(12):1237-1243. PubMed ID: 31538503
    [No Abstract]   [Full Text] [Related]  

  • 29. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reporting of adverse drug reactions: practice in the UK.
    Morrison-Griffiths S; Pirmohamed M; Walley T
    Nurs Times; 1998 Mar 11-17; 94(10):52-4. PubMed ID: 9735778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions.
    Bracchi RC; Tseliou F; Copeland L; Routledge PA; Thomas A; Woods F; Adams A; Walker J; Jadeja M; Atkinson MD; Ashfield-Watt P
    Br J Clin Pharmacol; 2021 Aug; 87(8):3344-3348. PubMed ID: 33386761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Under-reporting of gastrointestinal bleeding associated with anticoagulant use using the UK Yellow Card Scheme.
    Shuttleworth P; Baker J; Clark E
    Int J Clin Pharm; 2023 Aug; 45(4):1014-1018. PubMed ID: 37269441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.
    Francisca RDC; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
    Expert Opin Drug Saf; 2018 Oct; 17(10):975-982. PubMed ID: 30107752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New initiatives for pharmacovigilance in South Korea: introducing the Korea Institute of Drug Safety and Risk Management (KIDS).
    Shin JY; Jung SY; Ahn SH; Lee SH; Kim SJ; Seong JM; Chung SY; Park BJ
    Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1115-22. PubMed ID: 25251052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse drug reactions in neonates: could we be documenting more?
    Hawcutt DB; O'Connor O; Turner MA
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and clinical gains of nurse-led medication monitoring profiles.
    Gabe ME; Jordan SE
    J Nurs Manag; 2014 Apr; 22(3):331-49. PubMed ID: 23701013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The new EU legislation on pharmacovigilance and changing models for drug development.
    Callréus T
    Drug Saf; 2011 Jun; 34(6):529-30; author reply 530-1. PubMed ID: 21585224
    [No Abstract]   [Full Text] [Related]  

  • 38. Adverse drug reaction teaching in UK undergraduate medical and pharmacy programmes.
    Cox AR; Marriott JF; Wilson KA; Ferner RE
    J Clin Pharm Ther; 2004 Feb; 29(1):31-5. PubMed ID: 14748895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacovigilance in Europe.
    Johnson CL; Hutchinson JA
    Transplantation; 2015 Aug; 99(8):1542-3. PubMed ID: 26308299
    [No Abstract]   [Full Text] [Related]  

  • 40. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.